周二，H.C. Wainwright维持对Entrada Therapeutics股票的买入评级，目标价为USD 20.00。这家市值4.76亿美元的生物科技公司目前市盈率为12.79，估值具有吸引力，并且收到了重要的监管消息。该公司分析师Boobalan ...

Entrada Therapeutics is finally able to get its Duchenne muscular dystrophy candidate (DMD) back on track after the FDA ...

Entrada Therapeutics gains FDA clearance for its Phase 1b ELEVATE-44-102 study, evaluating ENTR-601-44 in adult Duchenne ...

Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with Duchenne muscular dystrophy - - Follows recently received ...

Shares of Entrada Therapeutics rose after regulators removed a clinical hold and said its lead product candidate could be studied as a treatment for Duchenne muscular dystrophy. The stock was up 9.5% ...

Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with ...

Entrada Therapeutics (TRDA) announced that the United States Food and Drug Administration has lifted the clinical hold on ENTR-601-44 and ...

波士顿 - 根据 InvestingPro 数据显示，市值4.76亿美元且财务状况良好的生物科技公司Entrada Therapeutics, Inc. (NASDAQ: TRDA )已获得美国食品和药物管理局（FDA）批准，可以开展其杜氏肌营养不良症（DMD）实验性治疗药物ENTR-601-44的1b期临床试验。此前，英国药品和保健品监管局也批准了相关研究。

Entrada Therapeutics' innovative Endosomal Escape Vehicle platform, poised to revolutionize drug delivery. Click here to read ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...